Histogen Files Investigational New Drug Application for HST-003

Histogen submitted an Investigational New Drug application with FDA to initiate a U.S. Phase I/II clinical trial to evaluate human extracellular matrix HST-003 (hECM:HST-003) plus microfracture in the knee to regenerate hyaline cartilage.

Histogen’s hECM is intended for hyaline cartilage regeneration for the treatment of articular...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us